Cardiovascular Diabetology

JULY 7, 2024

Objective Population-based national data on the trends in expenditures related to coexisting atherosclerotic cardiovascular diseases (ASCVD) and diabetes is scarce.

Diabetes 72

Diabetes Cardiovascular Disease Drug Costs Medicaid 72

DAIC

JUNE 4, 2024

These draft LCDs recognize the importance of quantifying coronary artery plaque, which underscores the pivotal role HeartFlow technology plays in diagnosing and managing treatment for patients in need of cardiovascular care. For more information: www.heartflow.com If you enjoy this content, please share it with a colleague

Medicare 104

Medicare Plaque Reimbursement Technology 104

American College of Cardiology

JANUARY 3, 2025

The Centers for Medicare and Medicaid Services (CMS) created two new G codes in the 2025 Medicare Physician Fee Schedule final rule that will provide reimbursement for atherosclerotic cardiovascular disease (ASCVD) risk assessment and risk management services.

Medicare 49

Medicare Reimbursement CMS Medicaid 49

DAIC

JULY 9, 2024

He completed his postgraduate training in cardiovascular disease and nuclear cardiology at Emory School of Medicine and is board certified in internal medicine and cardiovascular disease. He received his bachelor’s degree from Harvard University and his medical degree from Washington University in St. Louis, Missouri.

Innovation 111

Innovation Health Disparities Cardiovascular Disease Medicaid 111

American College of Cardiology

FEBRUARY 1, 2025

Initiatives such as the World Health Organization's "Medication Without Harm" and the Centers for Medicare and Medicaid Services' (CMS) expanded quality measures aim to reduce preventable emergency visits and hospital admissions due to medication-related harm. All are members of ACC’s Cardiovascular Team Member Section.

Cardiovascular Disease 40

Cardiovascular Disease Coronary Artery Disease CMS Hospital 40

DAIC

JUNE 18, 2024

We look forward to working with FDA, Centers for Medicare & Medicaid Services, and respective physician societies to bring this technology t­­o U.S. patients as soon as possible to elevate the standard of care for cardiovascular disease treatment.” “The

Coronary Artery Disease 105

Coronary Artery Disease Technology Stents Stent 105

CardiacWire

MARCH 24, 2024

Less than two weeks after Novo Nordisk’s weight-loss drug Wegovy gained expanded FDA approval for cardiovascular event risk reduction, CMS issued a new Medicare Part D guidance that allows coverage of obesity drugs for senior patients with “an additional medically accepted indication”… like cardiovascular disease.

Medicare 59

Medicare Obesity CMS Medicaid 59